Edgar Hernández-Leiva1, Paula Alvarado1, Rodolfo José Dennis2. 1. Department of Cardiology, Fundación Cardioinfantil - Instituto de Cardiología, Bogotá DC, Colombia. 2. Internal Medicine, Fundación Cardioinfantil - Instituto de Cardiología, Bogotá DC, Colombia.
Abstract
OBJECTIVE: The objective of this study was to calculate the direct costs of postoperative atrial fibrillation (POAF) in a high-complexity cardiovascular hospital. METHODS: We performed a cost analysis with a pairwise-matched design. Twenty-two patients with POAF and 22 patients without this complication were included. Pair-matching was performed (1:1) based on the following criteria: identical type of surgery, similar EuroSCORE II values, and absence of any other postoperative complication. RESULTS: The total hospital cost was significantly higher in the POAF group than in the non-POAF group (US$ 10,880 [± 2,688] vs. US$ 8,856 [± 1,782], respectively, for each patient; P=0.005). This difference was attributable to postoperative costs (US$ 3,103 [± 1,552] vs. US$ 1,238 [± 429]; P=0.0001) for patients with or without POAF, respectively. The median postoperative lengths of stay were 9 (range 5-17) and 5 (3-9) days for patients with and without POAF (P=0.032), respectively. Preoperatively, no differences were found in the EuroSCORE II values (median 1.7 vs. 1.6, respectively; P=0.91) or direct costs (US$ 1,127 vs. US$ 1,063, respectively; P=0.56) between POAF and non-POAF groups. CONCLUSION: POAF generates a high economic burden in the overall costs of cardiac surgery, and our results reveal the differential contribution of each of the evaluated factors. This information, which was previously unavailable in this setting, is essential for the development of more effective prevention strategies.
OBJECTIVE: The objective of this study was to calculate the direct costs of postoperative atrial fibrillation (POAF) in a high-complexity cardiovascular hospital. METHODS: We performed a cost analysis with a pairwise-matched design. Twenty-two patients with POAF and 22 patients without this complication were included. Pair-matching was performed (1:1) based on the following criteria: identical type of surgery, similar EuroSCORE II values, and absence of any other postoperative complication. RESULTS: The total hospital cost was significantly higher in the POAF group than in the non-POAF group (US$ 10,880 [± 2,688] vs. US$ 8,856 [± 1,782], respectively, for each patient; P=0.005). This difference was attributable to postoperative costs (US$ 3,103 [± 1,552] vs. US$ 1,238 [± 429]; P=0.0001) for patients with or without POAF, respectively. The median postoperative lengths of stay were 9 (range 5-17) and 5 (3-9) days for patients with and without POAF (P=0.032), respectively. Preoperatively, no differences were found in the EuroSCORE II values (median 1.7 vs. 1.6, respectively; P=0.91) or direct costs (US$ 1,127 vs. US$ 1,063, respectively; P=0.56) between POAF and non-POAF groups. CONCLUSION:POAF generates a high economic burden in the overall costs of cardiac surgery, and our results reveal the differential contribution of each of the evaluated factors. This information, which was previously unavailable in this setting, is essential for the development of more effective prevention strategies.
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Carlo Rostagno; Mark La Meir; Sandro Gelsomino; Lorenzo Ghilli; Alessandra Rossi; Enrico Carone; Lucio Braconi; Gabriele Rosso; Francesco Puggelli; Alessio Mattesini; Pier Luigi Stefàno; Luigi Padeletti; Jos Maessen; Gian Franco Gensini Journal: J Cardiothorac Vasc Anesth Date: 2010-05-31 Impact factor: 2.628
Authors: Ioanna Kosmidou; Shmuel Chen; A Pieter Kappetein; Patrick W Serruys; Bernard J Gersh; John D Puskas; David E Kandzari; David P Taggart; Marie-Claude Morice; Paweł E Buszman; Andrzej Bochenek; Erick Schampaert; Pierre Pagé; Joseph F Sabik; Thomas McAndrew; Björn Redfors; Ori Ben-Yehuda; Gregg W Stone Journal: J Am Coll Cardiol Date: 2018-02-20 Impact factor: 24.094
Authors: Marie Lamberigts; Lucas Van Hoof; Tine Proesmans; Pieter Vandervoort; Lars Grieten; Peter Haemers; Filip Rega Journal: JMIR Mhealth Uhealth Date: 2021-04-15 Impact factor: 4.773